DAPPAR-AF

Dabigatran for Peri-Procedural Anticoagulation During Radiofrequency Ablation
of Atrial Fibrillation (2013, ongoing)

Condition

Radiofrequency ablation of atrial fibrillation

Close this section

Objective

To evaluate the efficacy and safety of dabigatran in peri-procedural anticoagulation during ablation of atrial fibrillation

Close this section

Trial design

Prospective, open-label phase IV study
Active treatment: dabigatran 150 mg twice daily (110 mg twice daily in high-risk groups for bleeding and patients >80 years) for at least 30 days prior to the ablation procedure and for 90 days post ablation. Dabigatran will be initiated 8 hours post sheath removal and continued twice daily during the 3 month follow-up
Control treatment: historical data using other OAC methods for pulmonary vein ablation

Close this section

Endpoints

Primary outcome measures: incidence of peri-procedural major bleeding complications

Close this section

Trial participants

~ 200 patients, aged ≥18 years, untergoing first-time catheter ablation for paroxysmal or persistent symptomatic AF. At least one episode of AF must have been documented by ECG, Holter, loop recorder, telemetry, or transtelephonic monitoring within 24 months of entry in the trial

Close this section

Reference

ClinicalTrials.gov (NCT01468155)

Close this section

Corresponding author

Allan Skanes, MD, FRCPC, Lawson Health Research Institute, Schulich School of Medicine & Dentistry, Western University, 339 Windermere Road, Rm ALL-135, London, Ontario, Canada, askanes@uwo.ca

Close this section

Back To List

Recommend pageBack to top